According to DelveInsight's estimates, the corneal ulcer
market in 7MM is expected to show positive growth, during the
forecast period (2024–2034), mainly attributed to the anticipated
launch of emerging therapies and the increasing cases of corneal
ulcer.
LAS VEGAS, June 25, 2024 /PRNewswire/ --
DelveInsight's Corneal Ulcer Market
Insights report includes a comprehensive understanding of
current treatment practices, corneal ulcer emerging drugs, market
share of individual therapies, and current and forecasted market
size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Corneal Ulcer Market Report
- According to DelveInsight's analysis, the market size for
corneal ulcers is expected to grow significantly by 2034.
- CL-related infectious keratitis has been shown to exhibit a
female predominance of 57–69%, whereas trauma-related
infectious keratitis is associated with a male predominance of
74–78%.
- Leading corneal ulcer companies such as Dompé
Farmaceutici S.p.A, Claris Biotherapeutics, Inc. ReGenTree,
LLC, and others are developing novel corneal ulcer drugs that
can be available in the corneal ulcer market in the coming
years.
- The promising corneal ulcer therapies in the pipeline
include rhNGF, RGN-259, CSB-001, and others.
Discover which therapies are expected to grab the major corneal
ulcer market share @ Corneal Ulcer Market Report
Corneal Ulcer Overview
A corneal ulcer is a serious condition characterized by an open
sore on the cornea, the clear, dome-shaped surface that covers the
front of the eye. This ulcer can result from various causes,
including bacterial, viral, fungal, or parasitic infections. Common
bacterial culprits include Pseudomonas aeruginosa and
Staphylococcus aureus, often linked to contact lens wearers who do
not adhere to proper hygiene practices. Viral infections,
particularly from the herpes simplex virus, can also lead to
corneal ulcers. Additionally, eye injuries, dry eye syndrome, and
inflammatory disorders like rheumatoid arthritis can contribute to
their development.
Symptoms of a corneal ulcer typically include severe eye pain,
redness, tearing, discharge, blurred vision, and a sensation of
something being in the eye. In advanced cases, a white or gray spot
may be visible on the cornea. Light sensitivity and swelling of the
eyelids can also occur. Immediate medical attention is crucial to
prevent complications such as permanent vision loss or
scarring.
Diagnosis of a corneal ulcer involves a comprehensive eye
examination. An ophthalmologist may use a slit lamp, or a
specialized microscope, to closely inspect the cornea. Fluorescein
dye is often applied to the eye to highlight the ulcer and assess
its size and depth. In some cases, cultures or scrapings from the
ulcer may be taken to identify the infectious organism responsible,
allowing for targeted treatment. Early and appropriate intervention
is essential to manage this potentially sight-threatening condition
effectively.
Corneal Ulcer Epidemiology Segmentation
The corneal ulcer epidemiology section provides insights into
the historical and current corneal ulcer patient pool and
forecasted trends for the 7MM. It helps recognize the causes of
current and forecasted patient trends by exploring numerous studies
and views of key opinion leaders.
The corneal ulcer market report proffers epidemiological
analysis for the study period 2020–2034 in the 7MM segmented
into:
- Total Incident Cases of Corneal Ulcer
- Gender-specific Incident Cases of Corneal Ulcer
- Cause-specific Incident Cases of Corneal Ulcer
- Age-specific Incident Cases of Corneal Ulcer
Corneal Ulcer Treatment Market
Early detection and swift treatment are vital for reducing
corneal scarring and maintaining vision. Accurate identification of
the causative organism, often using a comprehensive approach, is
key to effective treatment. Antibiotic and antifungal medications
play a central role in fighting the infection while removing
irritants and providing eye lubrication to support the healing
process. Broad-spectrum antibiotics are usually started based on
clinical judgment until laboratory testing identifies the specific
pathogen, allowing for customized antibiotic therapy.
Topical corticosteroids are occasionally given to decrease
inflammation in corneal ulcers, but their application is carefully
supervised because of the potential to hinder healing or encourage
microbial growth. In more serious situations, surgical procedures
such as corneal debridement, amniotic membrane transplantation, or
corneal transplantation may be required to eliminate infected
tissue and support recovery. Scientists are exploring innovative
therapies like growth factors and regenerative medicine to enhance
results for corneal ulcers.
For the treatment of bacterial corneal ulcers, only three drugs
have received FDA approval: ofloxacin, ciprofloxacin, and 1.5%
levofloxacin. However, of these, only ofloxacin and ciprofloxacin
are presently available on the commercial market. Other drugs like
gatifloxacin, moxifloxacin, and besifloxacin have not been tested
in clinical trials for FDA approval for this particular
condition.
To know more about corneal ulcer treatment guidelines, visit @
Corneal Ulcer Management
Corneal Ulcer Pipeline Therapies and Key Companies
The major key players of Dompé Farmaceutici S.p.A, Claris
Biotherapeutics, Inc. ReGenTree, LLC, and others that are
developing drugs for the treatment of corneal ulcer.
Recombinant human nerve growth factor (rhNGF) can increase nerve
fiber density in the subbasal layer of the cornea, aiding in the
healing of chronic corneal epithelial defects and ulcers in
individuals with Neurotrophic Keratitis. It also has a partial
benefit in improving tear function. Clinical trials conducted by
Dompé Farmaceutici S.p.A have assessed the effectiveness of rhNGF
at 20 µg/ml compared to a placebo in patients with stage 2 and 3
Neurotrophic Keratitis. The drug is currently undergoing Phase I/II
clinical development.
RGN-259, an eye drop solution derived from Tβ4 and
formulated without preservatives, is a pioneering treatment for dry
eye disease and neurotrophic keratitis (NK). Unlike conventional
drugs, RGN-259 takes a fresh approach to healing the cornea,
showcasing both reparative and anti-inflammatory characteristics.
ReGenTree is advancing this drug through Phase III clinical
trials.
Claris is presently engaged in developing CSB-001,
a human recombinant dHGF, designed specifically to treat
Neurotrophic keratitis. CSB-001 is applied as a 0.1% ophthalmic
solution. Its unique mechanism of action has demonstrated greater
efficacy compared to a comparable molecule in treating neurotrophic
keratitis. The company is currently enrolling participants for its
Phase I/II clinical trial.
The anticipated launch of these emerging therapies for corneal
ulcer are poised to transform the market landscape in the
coming years. As these cutting-edge therapies continue to mature
and gain regulatory approval, they are expected to reshape the
corneal ulcer market landscape, offering new standards of care
and unlocking opportunities for medical innovation and economic
growth.
Discover more about Corneal Ulcer drugs in development @
Corneal Ulcer Clinical Trials
Corneal Ulcer Market Dynamics
The dynamics of the corneal ulcer market are expected to change
in the coming years. The corneal ulcer market is being driven by
advancements in diagnostic technologies and treatment
options, facilitating earlier detection and more effective
management of the condition. Innovations such as molecular
diagnostics and imaging modalities have improved accuracy in
identifying causative pathogens and assessing ulcer severity,
guiding targeted therapies. Additionally, rising incidences of
ocular infections and injuries, coupled with growing
awareness among healthcare providers about the consequences of
untreated corneal ulcers, underscore the need for continuous
development in this therapeutic area.
Furthermore, potential therapies are being investigated for the
treatment of corneal ulcer, and it is safe to predict that the
treatment space will significantly impact the corneal
ulcer market during the forecast period. Moreover, the
anticipated introduction of emerging therapies with improved
efficacy and a further improvement in the diagnosis rate are
expected to drive the growth of the corneal ulcer market in
the 7MM.
However several factors may impede the growth of the corneal
ulcer market. Limited awareness among healthcare providers
and patients about the symptoms and consequences of corneal ulcers
delays diagnosis and treatment initiation. Additionally, the
high cost of advanced therapies and medications poses
a financial barrier, especially in developing regions where access
to healthcare resources is limited. Moreover, regulatory
complexities and stringent approval processes for new
treatments impede the introduction of novel therapies into the
market.
Moreover, corneal ulcer treatment poses a significant
economic burden and disrupts patients' overall well-being and
QOL. Furthermore, the corneal ulcer market growth may be
offset by failures and discontinuation of emerging
therapies, unaffordable pricing, market access and
reimbursement issues, and a shortage of healthcare
specialists. In addition, the undiagnosed, unreported cases
and the unawareness about the disease may also impact the
corneal ulcer market growth.
Corneal Ulcer Market
Report Metrics
|
Details
|
Study Period
|
2020–2034
|
Coverage
|
7MM [the United States,
the EU4 (Germany, France, Italy, and Spain) and the United Kingdom,
and Japan].
|
Key Corneal Ulcer
Companies
|
Dompé Farmaceutici
S.p.A, Claris Biotherapeutics, Inc. ReGenTree, LLC,
and others
|
Key Pipeline Corneal Ulcer Therapies
|
rhNGF, RGN-259,
CSB-001, and others
|
Scope of the Corneal Ulcer Market
Report
- Therapeutic Assessment: Corneal Ulcer current
marketed and emerging therapies
- Corneal Ulcer Market Dynamics: Key
Market Forecast Assumptions of Emerging Corneal Ulcer Drugs and
Market Outlook
- Competitive Intelligence Analysis: SWOT analysis
and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Corneal Ulcer
Market Access and Reimbursement
Download the report to understand which factors are driving
corneal ulcer market trends @ Corneal Ulcer Market
Trends
Table of Contents
1.
|
Corneal Ulcer
Key Insights
|
2.
|
Corneal Ulcer
Report Introduction
|
3.
|
Corneal Ulcer Overview
at a Glance
|
4.
|
Corneal Ulcer
Executive Summary
|
5
|
Corneal Ulcer
Key Events
|
6
|
Epidemiology and Market
Forecast Methodology
|
6.
|
Disease Background and
Overview
|
7.
|
Corneal Ulcer
Treatment and Management
|
8.
|
Corneal Ulcer
Guidelines
|
9.
|
Corneal Ulcer
Epidemiology and Patient
Population
|
10.
|
Patient
Journey
|
11.
|
Key Endpoints in
Corneal Ulcer
|
12.
|
Corneal Ulcer Marketed
Drugs
|
13.
|
Corneal Ulcer
Emerging Drugs
|
14.
|
7MM Corneal Ulcer Market
Analysis
|
15.
|
Market Access and
Reimbursement
|
16.
|
KOL Views
|
17.
|
Unmet Needs
|
18.
|
SWOT
Analysis
|
19.
|
Appendix
|
20.
|
DelveInsight
Capabilities
|
21.
|
Disclaimer
|
22.
|
About
DelveInsight
|
Related Reports
Corneal Ulcer Epidemiology Forecast
Corneal Ulcer Epidemiology Forecast – 2032 report
delivers an in-depth understanding of the disease, historical and
forecasted epidemiology as well as the corneal
ulcer epidemiology trends.
Corneal Ulcer Pipeline
Corneal Ulcer Pipeline Insight – 2024 report
provides comprehensive insights about the pipeline landscape,
pipeline drug profiles, including clinical and non-clinical stage
products, and the key corneal ulcer companies, including
OcuNexus Therapeutics, Recordati Rare Diseases, Santen S.A.S.,
FirstString Research, Regeneratetx, Stuart Therapeutics, EyeGate
Pharmaceuticals, Trefoil Therapeutics, AmebaGone Inc, Dobecure,
Editas medicine, among others.
Neurotrophic Keratitis Market
Neurotrophic Keratitis Market Insights, Epidemiology,
and Market Forecast – 2032 report deliver an in-depth
understanding of the disease, historical and forecasted
epidemiology, as well as the market trends, market drivers, market
barriers, and key neurotrophic keratitis companies, including
Allergan, Plc., Abbott Laboratories, Inc, Bausch & Lomb
Incorporated, Bayer AG, CooperVision, Dompe farmaceutici S.p.A.,
Johnson & Johnson, Novartis AG, ReGenTree, LLC., Walgreens,
among others.
Uveitis Market
Uveitis Market Insights, Epidemiology, and Market
Forecast – 2032 report deliver an in-depth understanding of the
disease, historical and forecasted epidemiology, as well as the
market trends, market drivers, market barriers, and key
uveitis companies, including Tarsier Pharma, Oculis Pharma,
Roche, Eli Lilly and Company, Acelyrin, Affibody Medical,
Eyevensys, Priovant Therapeutics, Inc, Santen Inc., ABIONYX Pharma,
OKYO Pharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market
Research firm focused exclusively on life sciences. It supports
pharma companies by providing comprehensive end-to-end solutions to
improve their performance. Get hassle-free access to all the
healthcare and pharma market research reports through our
subscription-based platform PharmDelve.
Contact Us
Shruti
Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo:
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/corneal-ulcer-market-to-increase-at-a-steady-growth-rate-during-the-study-period-20202034--delveinsight-302181247.html